These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24789266)

  • 21. A case of histiocytic lymphophagocytic panniculitis (Rosai-Dorfman disease) with positive autoantibodies.
    Wang F; Chen X; Wu W; Wang Z; Han J
    J Dtsch Dermatol Ges; 2015 Apr; 13(4):334-6. PubMed ID: 25819246
    [No Abstract]   [Full Text] [Related]  

  • 22. Multiple nodules and plaques on the face and trunk. Cutaneous Rosai-Dorfman disease (RDD).
    Wartman DG; Perry A; Werchniak AE
    Arch Dermatol; 2006 Nov; 142(11):1501-6. PubMed ID: 17116845
    [No Abstract]   [Full Text] [Related]  

  • 23. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to methotrexate and mercaptopurine.
    Horneff G; Jürgens H; Hort W; Karitzky D; Göbel U
    Med Pediatr Oncol; 1996 Sep; 27(3):187-92. PubMed ID: 8699998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dense Papules on the Face: A Quiz.
    Zhou H; Zhao Q; Zhao L; Shang Q; Li J; Geng S
    Acta Derm Venereol; 2019 Sep; 99(10):935-936. PubMed ID: 30938828
    [No Abstract]   [Full Text] [Related]  

  • 25. Venorelbine and methotrexate for the treatment of Rosai-Dorfman disease.
    Inoue S; Onwuzurike N
    Pediatr Blood Cancer; 2005 Jul; 45(1):84-5; author reply 86. PubMed ID: 15838858
    [No Abstract]   [Full Text] [Related]  

  • 26. Cutaneous Rosai-Dorfman disease: a systematic review and reappraisal of its treatment and prognosis.
    Dhrif O; Litaiem N; Lahmar W; Fatnassi F; Slouma M; Zeglaoui F
    Arch Dermatol Res; 2024 Jun; 316(7):393. PubMed ID: 38878198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cutaneous revelation of Rosai-Dorfman disease: 7 cases].
    Vuong V; Moulonguet I; Cordoliani F; Crickx B; Bezier M; Vignon-Pennamen MD; Flageul B; Bagot M; Petit A
    Ann Dermatol Venereol; 2013 Feb; 140(2):83-90. PubMed ID: 23395488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous Rosai-Dorfman disease after Covid 19 vaccination treated with thalidomide.
    Grimaldi M; Perino F; Moretta G; Antonelli F; Paradisi A; Ricci F; Abeni D; Didona B; Fania L
    Dermatol Ther; 2022 Nov; 35(11):e15864. PubMed ID: 36175132
    [No Abstract]   [Full Text] [Related]  

  • 29. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) treated with 2-chlorodeoxyadenosine.
    Tasso M; Esquembre C; Blanco E; Moscardó C; Niveiro M; Payá A
    Pediatr Blood Cancer; 2006 Oct; 47(5):612-5. PubMed ID: 16302214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease.
    Tu J; Chan J
    Australas J Dermatol; 2014 Nov; 55(4):279-81. PubMed ID: 23651297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idiosyncratic reaction to low dose methotrexate resulting in pancytopenia and cutaneous toxicity.
    Rajsekhar L; Chakravathy MS; Prasad AK; Srinivasan VR
    J Assoc Physicians India; 2002 Jun; 50():851-2. PubMed ID: 12240864
    [No Abstract]   [Full Text] [Related]  

  • 32. A case of cutaneous Rosai-Dorfman disease refractory to imatinib therapy.
    Gebhardt C; Averbeck M; Paasch U; Ugurel S; Kurzen H; Stumpp P; Simon JC; Treudler R
    Arch Dermatol; 2009 May; 145(5):571-4. PubMed ID: 19451502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous rosai-dorfman disease and morphea: coincidence or association?
    Chappell JA; Burkemper NM; Frater JL; Hurley MY
    Am J Dermatopathol; 2009 Jul; 31(5):487-9. PubMed ID: 19542928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate.
    Konstantinou MP; Tournier E
    Int J Dermatol; 2022 Nov; 61(11):1409-1411. PubMed ID: 35569068
    [No Abstract]   [Full Text] [Related]  

  • 35. Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patients.
    Wang KH; Chen WY; Liu HN; Huang CC; Lee WR; Hu CH
    Br J Dermatol; 2006 Feb; 154(2):277-86. PubMed ID: 16433797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous Rosai-Dorfman disease.
    Parrent T; Clark T; Hall D
    Cutis; 2012 Nov; 90(5):237-8. PubMed ID: 23270193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet's disease.
    Jorizzo JL; White WL; Wise CM; Zanolli MD; Sherertz EF
    J Am Acad Dermatol; 1991 Jun; 24(6 Pt 1):973-8. PubMed ID: 1678395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous Rosai-Dorfman disease associated with uveitis.
    Fukumoto T; Oka M; Masaki T; Sakaguchi M; Fukunaga A; Norose K; Sarayama Y; Imai H; Nishigori C
    Eur J Dermatol; 2017 Feb; 27(1):85-86. PubMed ID: 28073706
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of purely cutaneous ​Rosai-Dorfman disease with topical rapamycin.
    Balestri R; Magnano M; Pedrolli A; Girardelli CR; Rech G
    Clin Exp Dermatol; 2023 Apr; 48(5):545-547. PubMed ID: 36647561
    [No Abstract]   [Full Text] [Related]  

  • 40. Extensive purely cutaneous Rosai-Dorfman disease responsive to acitretin.
    Mebazaa A; Trabelsi S; Denguezli M; Sriha B; Belajouza C; Nouira R
    Int J Dermatol; 2007 Nov; 46(11):1208-10. PubMed ID: 17988346
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.